Drug Profile
MM P02 01
Alternative Names: MM-P02-01Latest Information Update: 29 Aug 2023
Price :
$50
*
At a glance
- Originator Myungmoon Pharm
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Growth disorders; Short stature
Most Recent Events
- 29 Aug 2023 Discontinued - Preclinical for Growth disorders in South Korea (unspecified route) (Myungmoon Pharm pipeline, August 2023)
- 29 Aug 2023 Discontinued - Preclinical for Short stature in South Korea (unspecified route) (Myungmoon Pharm pipeline, August 2023)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Growth-disorders in South Korea